Rongyu Liu, Rongyu Liu, Xinlin He, Xinlin He, Zhengyu Li, & Zhengyu Li. (2022). Positive clinical outcomes following therapy with programmed cell death protein 1/programmed cell death ligand 1 inhibitors in neuroendocrine carcinoma of the cervix. Frontiers Media S.A..
Чикаго стиль цитування (17-те видання)Rongyu Liu, Rongyu Liu, Xinlin He, Xinlin He, Zhengyu Li, та Zhengyu Li. Positive Clinical Outcomes Following Therapy with Programmed Cell Death Protein 1/programmed Cell Death Ligand 1 Inhibitors in Neuroendocrine Carcinoma of the Cervix. Frontiers Media S.A., 2022.
Стиль цитування MLA (9-ме видання)Rongyu Liu, et al. Positive Clinical Outcomes Following Therapy with Programmed Cell Death Protein 1/programmed Cell Death Ligand 1 Inhibitors in Neuroendocrine Carcinoma of the Cervix. Frontiers Media S.A., 2022.